Skip to content

Study · Animal study (in vivo) · mouse · 2016

5 results

Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment.

Wang L, Li P, Tang Z, Yan X, Feng B

Scientific reports16 Sept 2016Cited by 124 (Europe PMC)

PMID27633081 (opens in a new tab)PMCIDPMC5025740 (opens in a new tab)DOI10.1038/srep33251 (opens in a new tab)PepBankPUB-27633081
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

The mechanisms underlying the weight-loss effect of GLP-1 receptor agonists need further elucidation. The present study was performed to explore the effects of liraglutide and saxagliptin on the composition of the gut microbiota. Mice were randomly treated with saxagliptin or liraglutide for eight weeks. Their metabolic profiles were assessed, and 454 pyrosequencing of 16s rRNA of faeces was performed. Liraglutide induced a smaller body weight gain in mice. The pyrosequencing showed that liraglutide, but not saxagliptin, substantially changed the overall structure of the gut microbiota as well as the relative abundance of weight-relevant phylotypes. Subsequent ridge regression analyses indicated that, in addition to food intake (β = -0.182, p = 0.043 in phylotypes inversely correlated with body weight) and blood glucose level (β = -0.240, p = 0.039 in phylotypes positively correlated with body weight), the administration of liraglutide was another independent factor associated with the abundance of weight-relevant phylotypes (β = 0.389, p = 6.24e-5 in inversely correlated ones; β = -0.508, p = 2.25e-5 in positively correlated ones). These results evidenced that GLP-1 receptor agonist liraglutide could modulate the composition of the gut microbiota, leading to a more lean-related profile that was consistent with its weight-losing effect.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice treated for eight weeks, liraglutide induced a smaller body weight gain.

    In plain wordsIn mice, liraglutide led to less weight gain over eight weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight gain
    Study

    mousen: not reported in source

    mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide induced a smaller body weight gain in mice.
    1 context sentence
    Summary · context
    Mice were randomly treated with saxagliptin or liraglutide for eight weeks. Their metabolic profiles were assessed, and 454 pyrosequencing of 16s rRNA of faeces was performed.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, liraglutide, but not saxagliptin, substantially changed the overall structure of the gut microbiota.

    In plain wordsIn mice, liraglutide changed the overall make-up of gut bacteria, and saxagliptin did not.

    Peptide
    Liraglutide
    Outcome
    Not applicableOverall structure of the gut microbiota
    Study

    mousen: not reported in source

    mice
    Comparator
    Saxagliptin
    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The pyrosequencing showed that liraglutide, but not saxagliptin, substantially changed the overall structure of the gut microbiota as well as the relative abundance of weight-relevant phylotypes.
    1 context sentence
    Summary · context
    Mice were randomly treated with saxagliptin or liraglutide for eight weeks. Their metabolic profiles were assessed, and 454 pyrosequencing of 16s rRNA of faeces was performed.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice, liraglutide, but not saxagliptin, substantially changed the relative abundance of weight-relevant gut bacterial phylotypes.

    In plain wordsIn mice, liraglutide changed the share of gut bacteria linked to body weight, and saxagliptin did not.

    Peptide
    Liraglutide
    Outcome
    MixedRelative abundance of weight-relevant phylotypes
    Study

    mousen: not reported in source

    mice
    Comparator
    Saxagliptin
    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The pyrosequencing showed that liraglutide, but not saxagliptin, substantially changed the overall structure of the gut microbiota as well as the relative abundance of weight-relevant phylotypes.
    1 context sentence
    Summary · context
    Mice were randomly treated with saxagliptin or liraglutide for eight weeks. Their metabolic profiles were assessed, and 454 pyrosequencing of 16s rRNA of faeces was performed.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice, liraglutide administration was an independent factor linked to higher abundance of gut phylotypes inversely correlated with body weight.

    In plain wordsIn mice, liraglutide was linked to more of the gut bacteria that go with lower body weight.

    Peptide
    Liraglutide
    Outcome
    IncreaseLiraglutide as predictor of abundance of phylotypes inversely correlated with body weight
    Study

    mousen: not reported in source

    mice
    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Measurements

    Ridge regression beta
    0.389 beta
    inversely correlated phylotypes

    Source sentences

    Summary
    the administration of liraglutide was another independent factor associated with the abundance of weight-relevant phylotypes (β = 0.389, p = 6.24e-5 in inversely correlated ones; β = -0.508, p = 2.25e-5 in positively correlated ones).
    1 context sentence
    Summary · context
    Mice were randomly treated with saxagliptin or liraglutide for eight weeks. Their metabolic profiles were assessed, and 454 pyrosequencing of 16s rRNA of faeces was performed.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice, liraglutide administration was an independent factor linked to lower abundance of gut phylotypes positively correlated with body weight.

    In plain wordsIn mice, liraglutide was linked to fewer of the gut bacteria that go with higher body weight.

    Peptide
    Liraglutide
    Outcome
    DecreaseLiraglutide as predictor of abundance of phylotypes positively correlated with body weight
    Study

    mousen: not reported in source

    mice
    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Measurements

    Ridge regression beta
    −0.508 beta
    positively correlated phylotypes

    Source sentences

    Summary
    the administration of liraglutide was another independent factor associated with the abundance of weight-relevant phylotypes (β = 0.389, p = 6.24e-5 in inversely correlated ones; β = -0.508, p = 2.25e-5 in positively correlated ones).
    1 context sentence
    Summary · context
    Mice were randomly treated with saxagliptin or liraglutide for eight weeks. Their metabolic profiles were assessed, and 454 pyrosequencing of 16s rRNA of faeces was performed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.